SUCCESSES DRIVE INTEREST
In 2010, the U.S. Food and Drug Administration (FDA) approved sipuleucel-T (Provenge; Dendreon), the fi rst immune system-stimulating cancer therapy, for advanced prostate cancer. It involves obtaining a patient's immune cells, exposing them to a prostate cancer-associated antigen, and then injecting them back into the patient.
Attention to immunotherapies really began to soar last year, when the FDA approved ipilimumab (Yervoy; BristolMyers Squibb) for metastatic melanoma. (It blocks cytotoxic T-lymphocyte antigen that otherwise may inhibit T cells.) "It was as if a dam burst," explains Vonderheide, co-principal investigator for the CITN at UPenn.
Interest in immunotherapy is also rising as researchers turn to combination therapies in the hopes of preventing drug resistance and metastasis. Dendreon, for example, will provide funding to the CITN for a study later this year that will combine sipuleucel-T with a T-cell growth factor involved in maintaining normal T-cell number, interleukin-7 [IL-7 (Cytheris)], in patients with advanced prostate cancer.
"It can be hard for investigators to get access to other agents and hard to get companies to cooperate. The CITN has set up the infrastructure to make that happen," notes Dendreon's Mark Frohlich, MD, the company's chief medical offi cer.
"The CITN provides us access to prominent investigators with experience in immunotherapy as well as a costeffective way for us to get information about how our therapy works in combination with other biologic agents," adds Frohlich.
Similarly, Pfi zer will learn more about its investigational dendritic cell-activating monoclonal antibody CP-870,893, which targets CD40, in the CITN's fi rst trial. Led by Vonderheide, the trial will assess CP-870,893 in combination with chemotherapy in patients with pancreatic cancer.
CP-870,893 was developed years ago and tested in melanoma, says Pfi zer's James Merson, PhD, a senior vice president and head of Vaccine Research West in La Jolla, CA. Initial results weren't compelling, and with numerous immune modulators in the company's portfolio and limited resources to study them, partnering with the CITN made good business sense, he says. More importantly, "we want to make sure that a potential benefi t for patients is not blocked." Says NCI's Howard Streicher, MD, CITN project scientist: "If the network weren't there, these studies would not be possible." -Suzanne Rose ■ For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
CITN investigators plan to test these agents against various cancers in clinical trials, in the order listed, over the next 5 years:
• CP-870,893, a dendritic cell-activating monoclonal antibody, in pancreatic cancer • IL-15, a T-cell and natural killer cell growth factor, in lung, head and neck, and renal cancers, and melanoma • IL-7, a T-cell growth factor, in prostate cancer and melanoma • IDO (indoleamine 2,3-dioxygenase) inhibitors, for the inhibition of immunosuppressive enzyme IDO in melanoma and ovarian cancer • Flt3-ligand, a dendritic cell growth factor, in melanoma.
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